Article
Harnessing ALDH1A2 vulnerability in T-cell acute lymphoblastic leukemia
2025-03-14
Abstract excerpt
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with limited therapeutic options, particularly in the relapsed/refractory (R/R) setting. Unlike other hematological malignancies, which benefit from targeted immunotherapies, T-ALL remains reliant on chemotherapy, leading to poor outcomes in R/R cases. Identifying novel therapeutic vulnerabilities is crucial to improving the outcom...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 5e269fbf-1ba3-52b5-a06b-d83910ad6ed8
- DOI
- 10.1101/2025.03.11.642712
